IGF1 and myeloid sarcoma: While the succession of IGF-1/IGFBP levels in body fluids of MS and their clinical relevance has been reported (124–128), the glial source of such senescence markers associated with lesion activities was not previously recognized, and our results suggest that AST10.eae2 is the upstream regulator of the IGFBP-mediated SASP cascade.